Abstract: We introduced the structure of human papilloma virus（HPV）, the mechanism of prophylactic HPV vaccines and their clinical application. Three kinds of prophylactic HPV vaccines have been approved by FDA in the United States, including the quadrivalent HPV vaccine（Gardasil）, the bivalent HPV vaccine （Cervarix） and the nine-valent HPV vaccine （Gardasil9）. The Gardasil was designed to work on the HPV 6/11/16/18, the Cervarix on the HPV 16/18, and the Gardasil9 on the HPV 6/11/16/18/31/33/45/52/58. The data of clinical trials of prophylactic HPV vaccines and the clinical data post-marketing were reviewed. Three kinds of HPV vaccines were showed their persistent protective efficacy during the follow-up visit, up to now, without serious adverse reaction. Of course, it is necessary to evaluate unceasingly the efficacy, and to monitor long-term the potential adverse reaction. The bivalent HPV vaccine developed independently by our country has been doing the PhaseⅢ clinical trial. It is hopeful in near future that the cervical cancer vaccine be applied in Chinese women.

Key words: Papillomaviridae, Papillomavirus vaccines, Uterine cervical neoplasms